Healthcare
Sartorius Stedim Biotech S.A.(SDMHF)
Live Price
Offline$192.00
-5.88% today
1Y Change
-11.16%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $15.25B
- Revenue Growth
- +6.7%
- EPS Growth
- +50.8%
- Dividend Yield
- 0.4%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sartorius Stedim Biotech S.A. (SDMHF) is a Healthcare stock with a market cap of $15.25B and listed on OTC. The stock last traded around $192.00 and down 11.2% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +6.7%, EPS growth of +50.8%, a dividend yield of 0.4%. What stands out right now is revenue +6.7%, EPS +50.8%, free cash flow -69.4% with operating margin 18.5% and ROIC 5.5%. The dividend is present but secondary, with a yield around 0.4%. Valuation already assumes a fairly strong business story at P/E 56.9 and price/sales 5.1. Stock Foundry combines SDMHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.7% vs +7.6% peer median
Operating Margin
Near sector median
+18.5% vs +19.4% peer median
P/E
Above sector median
56.9 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +6.7% and EPS at +50.8%, with operating margin around 18.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | +1.1% | -3.2% | +6.4% |
2026 Feb 16, 2026 | -10.8% | +0.0% | -1.3% | -6.8% |
2025 Oct 16, 2025 | -21.1% | +0.0% | +12.3% | +2.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SDMHF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SDMHF Max Drawdown
-31.33%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SDMHF and SPY.
Company Overview
Sartorius Stedim Biotech S.A.
Other OTC
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
- Leadership
- Rene Faber
- IPO Date
- Aug 3, 2009
- Employees
- 10.0k
- Street Address
- Zone Industrielle Les Paluds
- Mailing
- Aubagne, 13781
- Region
- Aubagne, FR
- Reporting Currency
- USD
- Investor Line
- 33 4 42 84 56 00
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 56.9
- EV/EBITDA
- 20.6
- Price/Sales
- 5.1
- Price/Book
- 3.7
Growth
- Revenue
- +6.7%
- EPS
- +50.8%
- Free Cash Flow
- -69.4%
Profitability
- Gross Margin
- 44.7%
- Operating Margin
- 18.5%
- Net Margin
- 9.0%
- ROE
- 6.6%
- ROIC
- 5.5%
Balance Sheet
- Debt/Equity
- 0.64
- Current Ratio
- 1.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.